In this study, we characterized the molecular mechanism underlying the anti-tumor activity of ENb-TRAIL and evaluated its therapeutic efficacy in various cell lines from different cancer types which are inherently non-responsive to EGFR and DR4/5 targeted monotherapies. This evidence concerns the gene TNFRSF10A and cancer.